genetic vaccines
PHASE 3
Moderna logoNational Institutes of Health logo
Moderna develops vaccines based on messenger RNA (mRNA) to produce viral proteins in the body. They have yet to bring one to the market. In January, they began developing a vaccine for the coronavirus and since then the government has bankrolled Moderna’s efforts, providing nearly $1 billion. In partnership with National Institutes of Health, they found that the vaccine protects monkeys from the coronavirus. In March, the company put the first Covid-19 vaccine into human trials, which yielded promising results. The vaccine has progressed into Phase 3 testing, which began on July 27. The final trial is enrolling 30,000 healthy people at about 89 sites around the United States. On August 11, the government awarded the company an additional $1.5 billion in exchange for 100 million doses if the vaccine proves safe and effective.
In July, Moderna lost a patent dispute over some of their vaccine technology. The following month, the company stated that it could not be certain it was the first to make the inventions claimed in their patents, including its coronavirus vaccine.
Moderna logoNational Institutes of Health logo
Moderna develops vaccines based on messenger RNA (mRNA) to produce viral proteins in the body. They have yet to bring one to the market. In January, they began developing a vaccine for the coronavirus and since then the government has bankrolled Moderna’s efforts, providing nearly $1 billion. In partnership with National Institutes of Health, they found that the vaccine protects monkeys from the coronavirus. In March, the company put the first Covid-19 vaccine into human trials, which yielded promising results. The vaccine has progressed into Phase 3 testing, which began on July 27. The final trial is enrolling 30,000 healthy people at about 89 sites around the United States. On August 11, the government awarded the company an additional $1.5 billion in exchange for 100 million doses if the vaccine proves safe and effective.
In July, Moderna lost a patent dispute over some of their vaccine technology. The following month, the company stated that it could not be certain it was the first to make the inventions claimed in their patents, including its coronavirus vaccine.
- ۴.۵k
- ۲۰ شهریور ۱۳۹۹
دیدگاه ها (۱)
در حال بارگزاری
خطا در دریافت مطلب های مرتبط
